Notice of Allowability	Application No.	Applicant(s) NARA ET AL. Art Unit
	09/899,186 Examiner	
	Raymond Covington	1625
The MAILING DATE of this communicatio All claims being allowable, PROSECUTION ON THE MER herewith (or previously mailed), a Notice of Allowance (PTO NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATI of the Office or upon petition by the applicant. See 37 CFF	ITS IS (OR REMAINS) CLOSED in t OL-85) or other appropriate commun ENT RIGHTS. This application is su	his application. If not included ication will be mailed in due course. THIS
1. This communication is responsive to 10/10/03.		
2. 🔀 The allowed claim(s) is/are <u>1-26</u> .		
3. The drawings filed on are accepted by the Ex	aminer.	
 4. Acknowledgment is made of a claim for foreign pricate. a) All b) Some* c) None of the: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority 	s have been received. s have been received in Application rity documents have been received i	No
* Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING I noted below. Failure to timely comply will result in ABAN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be INFORMAL PATENT APPLICATION (PTO-152) whi 6. CORRECTED DRAWINGS (as "replacement sheets (a) including changes required by the Notice of Dra	DATE" of this communication to file a DONMENT of this application. submitted. Note the attached EXAM ch gives reason(s) why the oath or described by the oath or described by the submitted. It is person's Patent Drawing Review (———————————————————————————————————	MINER'S AMENDMENT or NOTICE OF declaration is deficient. PTO-948) attached In the Office action of drawings in the front (not the back) of 1.121(d). RIAL must be submitted. Note the
* Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING E noted below. Failure to timely comply will result in ABAN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be INFORMAL PATENT APPLICATION (PTO-152) whi 6. CORRECTED DRAWINGS (as "replacement sheets (a) including changes required by the Notice of Dra 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Exa Paper No./Mail Date Identifying indicia such as the application number (see 37 each sheet. Replacement sheet(s) should be labeled as suf.	DATE" of this communication to file a DONMENT of this application. submitted. Note the attached EXAM ch gives reason(s) why the oath or described by the oath or described	MINER'S AMENDMENT or NOTICE OF leclaration is deficient. PTO-948) attached In the Office action of drawings in the front (not the back) of 1.121(d). RIAL must be submitted. Note the OGICAL MATERIAL.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Lawrence Perry on March 4, 2003.

The application has been amended and Claim 1 has been rewritten, as follows:

Art Unit: 1625

1. (Currently Amended) A piperidine derivative represented by formula (1):

$$O_2N$$

$$R^2$$

$$X (CH_2)_mR^3$$

wherein;

m represents an integer of 0 to 5,

Rl and R2 independently represent a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group, a substituted or unsubstituted lower alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group;

R3 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ary1 group, or a substituted or unsubstituted heterocyclic group; and

X represents a bond or CO;

or a pharmaceutically acceptable salt thereof,

wherein the heterocyclic groups in Rl, R2 and R3 independently represent benzopyranyl, l,4-benzodioxanyl, l,3-benzodioxolyl, furyl, imidazolyl, imidazothiazolyl, indolyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyrazolinyl, pyrazolyl, thiadiazolyl, thienyl.

Application/Control Number: 09/899,186

Art Unit: 1625

The following is an examiner's statement of reasons for allowance: In light of the amendment by applicants and the examiner's amendment set forth herein above the rejection under 35 USC 112 has been overcome. Further, the claims as so amended are neither taught nor disclosed by the prior art.

Accordingly, claims 1-26 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond Covington whose telephone number is (703) 308-4704. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, J. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Raymond Covington

Examiner

Art Unit 1625

∕⁄∙ RKC

RITA DESAI PRIMARY EXAMINER